Year: 2022

Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 202438 patients have been implanted with Prima System in pivotal trial Data will also play an important supporting role in US regulatory submissionParis, France, December 15, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in atrophic dry age-related macular degeneration (dry AMD), also known as Geographic Atrophy. A total of 38 patients have...

 Dupixent®(dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularisApproval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients experienced a clinically meaningful reduction in itch at 24 weeks Dupixent also significantly reduced skin lesions and improved health-related quality of life compared to placebo In Europe, about 70,000 adults living with prurigo nodularis are most in need of new treatment options Dupixent now approved to treat four chronic inflammatory diseases in the EUParis and Tarrytown, N.Y. Dec. 15, 2022 The European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Prurigo...

Idorsia to host an investor webcast to discuss the Phase 3 program today at 15:00hrs CETAllschwil, Switzerland – December 15, 2022Idorsia Ltd (SIX: IDIA) today announced that the first patient has entered screening to participate in OPUS, a Phase 3 program to investigate the efficacy and safety of cenerimod, Idorsia’s novel, highly selective S1P1 receptor modulator, as an oral treatment for adult patients with moderate to severe systemic lupus erythematosus. Systemic lupus erythematosus (SLE), the most common form of lupus, is an autoimmune disease. While the cause of SLE is not fully known, T and B lymphocytes are considered the key immune cells that play a role in the development of SLE. In individuals with SLE, both T and B cells become overactive, infiltrate different tissues and produce autoantibodies, leading to inflammation and...

Magnite’s Demand Manager Mobile lifts SmartNews’ programmatic ad spend NEW YORK and TOKYO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the world’s largest independent omnichannel sell side advertising platform, today announced that SmartNews, Inc., a global leader in redefining information and news discovery, has selected Magnite as their preferred SSP in the US and implemented Magnite’s Demand Manager mobile app solution, resulting in a large lift to SmartNews’ programmatic advertising business. Buyers can now access SmartNews inventory through a transparent Prebid pipeline. SmartNews’ mission is to revolutionize the way consumers engage with and discover information through their support of diverse, high quality journalistic sources. With Magnite’s Demand Manager Mobile, a fully open source Prebid Mobile SDK-based...

LOS ANGELES, Dec. 14, 2022 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (the “Company”) announced today that Chief Executive Officer Ben Kohn and the other Section 16 officers of the Company will sell in the aggregate approximately 0.6 million shares of common stock, and the sale proceeds will be applied to cover the executives’ tax withholding obligations in connection with the settlement of approximately 1.2 million vested restricted stock units (“RSUs”) previously granted to the executives. Pursuant to the Company’s current practices, withholding tax obligations arising from RSU settlements are being satisfied by the sale of shares by the recipients solely to cover the taxes related to such transactions. Following the RSU settlement and his sale to cover tax obligations, Mr. Kohn will beneficially own...

James M. Moses Photo courtesy of First Hawaiian, Inc.HONOLULU, Dec. 14, 2022 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ:FHB), the parent company of First Hawaiian Bank, announced today that it has appointed James M. Moses as Vice Chairman and Chief Financial Officer (CFO) of First Hawaiian, Inc. and First Hawaiian Bank, effective January 3, 2023. “Jamie brings more than 20 years of diverse banking experience to the team. His track record of driving financial growth in complex organizations makes him a great fit for First Hawaiian. We look forward to integrating his expertise into our ongoing initiatives,” said Bob Harrison, First Hawaiian, Inc. Chairman, President and CEO. “I want to thank Ralph Mesick for serving as our interim CFO and effectively guiding us through this transition period.” Moses joins the company from...